Xenetic Biosciences, INC

Xenetic Biosciences announced its second quarter 2026 financial results, reporting a 12% increase in royalty revenue to $0.7 million, while net loss widened to $0.9 million.

Xenetic Biosciences announced first quarter 2026 financial results, highlighting a 36% increase in royalty revenue and progress in its DNase oncology platform development.

Xenetic Biosciences has awarded 100,000 shares of restricted stock to its Interim CEO and CFO, James Parslow.

Xenetic Biosciences, Inc. announced its full-year 2025 financial results, highlighting progress in its DNase-based immuno-oncology program and a strengthened cash position.

Xenetic Biosciences, Inc. has again adjourned its 2025 Annual Meeting of Stockholders due to a persistent lack of a requisite quorum.

Xenetic Biosciences, Inc. adjourned its 2025 Annual Meeting of Stockholders until January 8, 2026, due to a lack of quorum.

Xenetic Biosciences reports increased royalty revenue in Q2 2026 but continues to face operational losses, while undergoing a strategic review process that may lead to significant corporate changes.

Xenetic Biosciences reported increased royalty revenue but a wider net loss for Q3 2025, driven by higher research and development expenses and legal costs, while initiating a strategic review.

Xenetic Biosciences reported a reduced net loss in Q2 2025, driven by lower operating expenses, as it continues to advance its DNase immune-oncology program.

Xenetic Biosciences reports increased royalty revenue and reduced operating expenses in Q1 2025, while continuing to advance its DNase technology for cancer treatment.

Xenetic Biosciences reported its Q3 2024 financial results, highlighting a focus on advancing its DNase platform for cancer treatment and ongoing royalty revenue from its PolyXen technology.

Xenetic Biosciences' second quarter 2024 results show an increase in royalty revenue but also a net loss, with a focus on advancing their DNase platform.

Xenetic Biosciences, Inc. has amended its annual report to provide detailed disclosures on executive compensation, board governance, and significant consulting agreements with related parties.

Xenetic Biosciences, Inc. reported a significant reduction in net loss for 2025, driven by increased royalty revenue and a successful $4.0 million public offering, as it continues to advance its proprietary DNase technology for solid tumors.

Xenetic Biosciences files an amendment to its 2024 annual report to include details on equity award grant practices and updated certifications.

Xenetic Biosciences files an amendment to its 2024 annual report to include information previously omitted regarding directors, executive officers, compensation, and related matters.

Xenetic Biosciences' 2024 10-K filing highlights the company's focus on advancing its DNase technology for cancer treatment amid ongoing financial losses.

Xenetic Biosciences has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

Interim CEO and CFO James F. Parslow was granted 100,000 shares of restricted common stock in Xenetic Biosciences.

Xenetic Biosciences Director Alexey Vinogradov was granted 2,500 stock options with an exercise price of $2.17, vesting in one year.

Xenetic Biosciences, Inc. Director Firdaus J. Dastoor was granted 2,500 stock options with an exercise price of $2.17, vesting in one year.

Xenetic Biosciences Director Roger D. Kornberg acquired 2,500 stock options with an exercise price of $2.17, vesting on December 31, 2026.

Xenetic Biosciences Director Grigory G. Borisenko was granted 2,500 stock options with an exercise price of $2.17, vesting in one year.

Director Roger D. Kornberg acquired 2,500 stock options in Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. announced the adjournment of its 2025 Annual Meeting of Stockholders due to a lack of quorum, rescheduling it for January 8, 2026.

Xenetic BioSciences, Inc. announced its 2024 Annual Meeting of Stockholders will be held virtually on December 11, 2024, to vote on director elections, auditor ratification, and executive compensation.

Xenetic Biosciences, Inc. announces its 2025 Annual Meeting of Stockholders to address director elections, auditor ratification, and executive compensation.

Xenetic Biosciences announces its annual stockholder meeting to be held on December 11, 2024, outlining key proposals for voting, including the election of directors and ratification of the company's accounting firm.

Xenetic Biosciences announces its annual meeting of stockholders to be held virtually on December 11, 2024, featuring proposals including director elections, auditor ratification, and executive compensation votes.

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported beneficial ownership of 6.00% of Xenetic Biosciences, Inc. common stock as of March 31, 2026.

Renaissance Technologies LLC and its parent company have disclosed a 7.79% beneficial ownership stake in Xenetic Biosciences, Inc. as of an event date in late 2025.